Article Versions Notes

Ghimessy ÁK, Gellert Á, Schlegl E, Hegedus B, Raso E, Barbai T, Timar J, Ostoros G, Megyesfalvi Z, Gieszer B, et al. KRAS Mutations Predict Response and Outcome in Advanced Lung Adenocarcinoma Patients Receiving First-Line Bevacizumab and Platinum-Based Chemotherapy. Cancers. 2019; 11(10):1514. https://doi.org/10.3390/cancers11101514

Ghimessy, Áron Kristof, Áron Gellert, Erzsebet Schlegl, Balazs Hegedus, Erzsebet Raso, Tamas Barbai, Jozsef Timar, Gyula Ostoros, Zsolt Megyesfalvi, Balazs Gieszer, and et al. 2019. "KRAS Mutations Predict Response and Outcome in Advanced Lung Adenocarcinoma Patients Receiving First-Line Bevacizumab and Platinum-Based Chemotherapy" Cancers 11, no. 10: 1514. https://doi.org/10.3390/cancers11101514

Ghimessy, Á. K., Gellert, Á., Schlegl, E., Hegedus, B., Raso, E., Barbai, T., Timar, J., Ostoros, G., Megyesfalvi, Z., Gieszer, B., Moldvay, J., Renyi-Vamos, F., Lohinai, Z., Hoda, M. A., Klikovits, T., Klepetko, W., Laszlo, V., & Dome, B. (2019). KRAS Mutations Predict Response and Outcome in Advanced Lung Adenocarcinoma Patients Receiving First-Line Bevacizumab and Platinum-Based Chemotherapy. Cancers, 11(10), 1514. https://doi.org/10.3390/cancers11101514